PDF下载 ( 766 KB)
代谢功能障碍与酒精相关性肝病：新概念与新进展
DOI: 10.12449/JCH260426
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：林儒焘负责设计论文框架，起草论文；徐斐负责数据收集，论文修改；辛鑫负责论文修改；胡义扬及冯琴负责拟定写作思路，指导撰写文章并最后定稿。林儒焘和徐斐为共同第一作者。
Metabolic-dysfunction and alcohol-associated liver disease： A new concept and recent advances
-
摘要: 2023年，国际多学会提出了“代谢功能障碍与酒精相关性肝病（MetALD）”这一概念，用以指代同时存在代谢功能障碍和中等量饮酒的脂肪肝人群。近年来，该领域的证据体系正迅速发展与完善。本文综述了MetALD的背景与定义、流行病学特征及自然史、临床表型、诊断评估方法以及治疗研究的最新进展，并对未来的研究方向进行展望。
-
关键词:
- 代谢功能障碍与酒精相关性肝病 /
- 代谢相关脂肪性肝病 /
- 酒精性肝病
Abstract: In 2023， multiple international societies proposed the concept of metabolic-dysfunction and alcohol-associated liver disease （MetALD） to characterize patients with steatotic liver disease who exhibit metabolic dysfunction and consume alcohol at a moderate level. In recent years， the evidence system in this field has been constantly developed and improved. This article reviews the latest research advances in MetALD from the aspects of background， definition， epidemiological characteristics， natural history， clinical phenotype， diagnostic and assessment methods， and treatment regimens， as well as the directions for future investigation. -
注： PEth，磷脂酰乙醇；MAFLD，代谢相关脂肪性肝病；MetALD，代谢功能障碍与酒精相关性肝病；ALD，酒精性肝病。本图改编自文献［ 35］，经授权许可使用，许可号：6086371097660。
图 1 应用自报饮酒与PEth结果及其他临床信息综合判断脂肪肝亚型
Figure 1. Comprehensive determination of steatotic liver disease subtypes using self-reported alcohol consumption and PEth results as well as other clinical information
-
[1] RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79( 6): 1542- 1556. DOI: 10.1016/j.jhep.2023.06.003. [2] Chinese Society of Hepatology, Chinese Medical Association. Guidelines for prevention and treatment of metabolic-related(nonalcoholic) fatty liver disease(2024 edition)[J]. J Prac Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163. [3] LOOMBA R, WONG VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59( 2): 150- 156. DOI: 10.1111/apt.17846. [4] ISRAELSEN M, TORP N, JOHANSEN S, et al. MetALD: New opportunities to understand the role of alcohol in steatotic liver disease[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 866- 868. DOI: 10.1016/S2468-1253(23)00206-6. [5] European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), European Association for the Study of Obesity(EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81( 3): 492- 542. DOI: 10.1016/j.jhep.2024.04.031. [6] JIANG ZY, ZHANG BB, LI J, et al. Interpretation of metabolic dysfunction and alcohol-related liver disease: Position statement by an expert panel on alcohol-related liver disease(2024 edition)[J]. J Clin Hepatol, 2025, 41( 3): 442- 445. DOI: 10.12449/JCH250308.江臻遥, 张彬彬, 李婕, 等.《2024年国际酒精相关肝病专家小组立场声明: 代谢功能障碍和酒精相关性肝病》解读[J]. 临床肝胆病杂志, 2025, 41( 3): 442- 445. DOI: 10.12449/JCH250308. [7] KIM D, LOOMBA R, AHMED A. Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023[J]. Clin Mol Hepatol, 2025, 31( 3): e235- e238. DOI: 10.3350/cmh.2024.1150. [8] TAMPAKI M, TSOCHATZIS E, LEKAKIS V, et al. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease(MetALD): A systematic review and meta-analysis[J]. Metabolism, 2025, 163: 156101. DOI: 10.1016/j.metabol.2024.156101. [9] YOON EL, PARK H, HONG HP, et al. Distinct characteristics of MetALD(metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population[J]. Hepatol Res, 2025, 55( 3): 410- 421. DOI: 10.1111/hepr.14133. [10] YANG AH, TINCOPA MA, TAVAGLIONE F, et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA[J]. Gut, 2024, 73( 12): 2045- 2053. DOI: 10.1136/gutjnl-2024-332917. [11] KIM D, DANPANICHKUL P, WIJARNPREECHA K, et al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023[J]. Clin Mol Hepatol, 2025, 31( 2): 382- 393. DOI: 10.3350/cmh.2024.0987. [12] ISRAELSEN M, TORP N, JOHANSEN S, et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: An analysis of data from a prospective cohort study[J]. Lancet Gastroenterol Hepatol, 2024, 9( 3): 218- 228. DOI: 10.1016/S2468-1253(23)00443-0. [13] OH JH, AHN SB, CHO S, et al. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort[J]. J Hepatol, 2024, 81( 5): 772- 780. DOI: 10.1016/j.jhep.2024.05.042. [14] TAMAKI N, KIMURA T, WAKABAYASHI SI, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality[J]. Aliment Pharmacol Ther, 2024, 60( 1): 61- 69. DOI: 10.1111/apt.18015. [15] OCHOA-ALLEMANT P, HUBBARD RA, KAPLAN DE, et al. Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease[J]. JAMA Intern Med, 2025, 185( 8): 986- 995. DOI: 10.1001/jamainternmed.2025.1809. [16] KIM GA, JEONG S, JANG H, et al. Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatotic liver disease with increased alcohol intake increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: A Korean nationwide study[J]. Liver Cancer, 2024, 13( 4): 426- 437. DOI: 10.1159/000535943. [17] YUN B, PARK H, AHN SH, et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: A nationwide study[J]. Am J Gastroenterol, 2025, 120( 2): 410- 419. DOI: 10.14309/ajg.0000000000002920. [18] MOON JH, JEONG S, JANG H, et al. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: A nationwide cohort study[J]. EClinicalMedicine, 2023, 65: 102292. DOI: 10.1016/j.eclinm.2023.102292. [19] ZHANG Q, XU F, WANG ZY, et al. Long-term risk of inflammatory bowel disease with MASLD: A large-scale prospective cohort study in UK biobank[J]. J Gastroenterol Hepatol, 2025, 40( 4): 855- 865. DOI: 10.1111/jgh.16880. [20] PENG Y, WANG P, LIU FB, et al. Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study[J]. Diabetes Obes Metab, 2025, 27( 4): 1940- 1949. DOI: 10.1111/dom.16186. [21] KIM DW, SON M, LEE HJ, et al. Chronic kidney disease risk associated with metabolic dysfunction-associated steatotic liver disease: A nationwide cohort study in Korea[J]. Hepatol Res, 2025, 55( 9): 1239- 1250. DOI: 10.1111/hepr.14226. [22] OH J, KIM BK, YOON JH, et al. Metabolic dysfunction-associated steatotic liver disease is associated with increased risk of kidney cancer: A nationwide study[J]. Cancers, 2024, 16( 18): 3161. DOI: 10.3390/cancers16183161. [23] MOON SY, SON M, CHO JH, et al. Association between metabolic dysfunction-associated steatotic liver disease and thyroid cancer[J]. Thyroid, 2025, 35( 1): 79- 86. DOI: 10.1089/thy.2024.0522. [24] SHIN WY, KANG ES, OH YH, et al. Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: A nationwide cohort study: MASLD, MetALD, and dementia risk[J]. BMC Gastroenterol, 2025, 25( 1): 308. DOI: 10.1186/s12876-025-03814-1. [25] LEE BP, MOLINA J, KIM S, et al. Association of alcohol and incremental cardiometabolic risk factors with liver disease: A national cross-sectional study[J]. Clin Gastroenterol Hepatol, 2025, 23( 12): 2205- 2213. DOI: 10.1016/j.cgh.2025.01.003. [26] LI MQ, CHEN WY, DENG Y, et al. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups[J]. Nutr Metab Cardiovasc Dis, 2024, 34( 9): 2085- 2094. DOI: 10.1016/j.numecd.2024.05.018. [27] JIA LY, RUI FJ, WU XY, et al. Exploration of the relationship between patients with MAFLD and MetALD for alcohol intake on all-cause mortality based on NHANES III data[J]. Chin J Hepatol, 2025, 33( 9): 862- 871. DOI: 10.3760/cma.j.cn501113-20241018-00547.贾乐遥, 芮法娟, 吴翔宇, 等. 基于NHANES III数据探究饮酒量与代谢相关脂肪性肝病及代谢和酒精相关脂肪变性肝病患者的全因死亡率关系[J]. 中华肝脏病杂志, 2025, 33( 9): 862- 871. DOI: 10.3760/cma.j.cn501113-20241018-00547. [28] XIONG ZK, LIN RT, CHEN BW, et al. Persistent binge drinking history associated with advanced liver fibrosis and all-cause mortality in MetALD[J]. Aliment Pharmacol Ther, 2025, 62( 11-12): 1100- 1107. DOI: 10.1111/apt.70286. [29] PETRIE E, GRAY M, BRIL F. Metabolic characteristics of patients with MetALD: Caveats of a new definition[J]. Liver Int, 2024, 44( 11): 2929- 2938. DOI: 10.1111/liv.16034. [30] SCHNEIDER KM, CAO F, HUANG HYR, et al. The lipidomic profile discriminates between MASLD and MetALD[J]. Aliment Pharmacol Ther, 2025, 61( 8): 1357- 1371. DOI: 10.1111/apt.70012. [31] LIU J, XIAO SH, HU SL, et al. Dissecting metabolic dysfunction- and alcohol-associated liver disease(MetALD) using proteomic and metabolomic profiles[J]. J Hepatol, 2025, 83( 5): 1035- 1045. DOI: 10.1016/j.jhep.2025.05.026. [32] CHEN HL, CHEN SY, LIU D, et al. Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study[J]. Cell Rep Med, 2025, 6( 1): 101884. DOI: 10.1016/j.xcrm.2024.101884. [33] TORP N, ISRAELSEN M, THIELE M, et al. Phosphatidylethanol in steatotic liver disease[J]. J Hepatol, 2025, 83( 5): 1189- 1203. DOI: 10.1016/j.jhep.2025.07.019. [34] TAVAGLIONE F, AMANGURBANOVA M, YANG AH, et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: A prospective study[J]. Aliment Pharmacol Ther, 2025, 61( 6): 1043- 1054. DOI: 10.1111/apt.18506. [35] LOOMBA R, HAGSTRÖM H, DÍAZ LA. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: Is this the new standard?[J]. Gastroenterology, 2025, 169( 6): 1103- 1107. DOI: 10.1053/j.gastro.2025.07.007. [36] TAVAGLIONE F, DÍAZ LA, AJMERA V, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification[J]. J Hepatol, 2025, 83( 5): 1023- 1034. DOI: 10.1016/j.jhep.2025.05.030. [37] VAZ J, NASR P, HELANDER A, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes[J]. J Hepatol, 2025, 83( 5): 1011- 1022. DOI: 10.1016/j.jhep.2025.04.019. [38] DIAZ LA, AJMERA V, ARAB JP, et al. An expert consensus Delphi panel in metabolic dysfunction- and alcohol-associated liver disease: Opportunities and challenges in clinical practice[J]. Clin Gastroenterol Hepatol, 2025, 24( 3): 633- 645.e4. DOI: 10.1016/j.cgh.2025.02.017. [39] ÅBERG F, HELENIUS-HIETALA J, PUUKKA P, et al. Binge drinking and the risk of liver events: A population-based cohort study[J]. Liver Int, 2017, 37( 9): 1373- 1381. DOI: 10.1111/liv.13408. [40] ARAB JP, DÍAZ LA, REHM J, et al. Metabolic dysfunction and alcohol-related liver disease(MetALD): Position statement by an expert panel on alcohol-related liver disease[J]. J Hepatol, 2025, 82( 4): 744- 756. DOI: 10.1016/j.jhep.2024.11.028. [41] FENG G, WONG VW, TARGHER G, et al. Non-invasive tests of fibrosis in the management of MASLD: Revolutionising diagnosis, progression and regression monitoring[J]. Gut, 2025, 74( 10): 1741- 1750. DOI: 10.1136/gutjnl-2025-335542. [42] DÍAZ LA, TAVAGLIONE F, MITTAL N, et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease(MetALD)[J]. Hepatol Commun, 2025, 9( 6): e0718. DOI: 10.1097/HC9.0000000000000718. [43] HYDES TJ, KENNEDY OJ, GLYN-OWEN K, et al. Liver fibrosis assessed via noninvasive tests is associated with incident heart failure in a general population cohort[J]. Clin Gastroenterol Hepatol, 2024, 22( 8): 1657- 1667. DOI: 10.1016/j.cgh.2024.03.045. [44] LIN RT, SUN QM, XIN X, et al. Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis[J]. Metabolism, 2024, 161: 156043. DOI: 10.1016/j.metabol.2024.156043. [45] HARRISON SA, SCHATTENBERG JM, TAUB R, et al. SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study[J]. J Hepatol, 2024, 80: S141- S142. DOI: 10.1016/S0168-8278(24)00708-6. [46] CHRYSAVGIS L, MOURELATOU NG, CHOLONGITAS E. Glucagon-like peptide-1 receptor agonists(GLP-1 RAs): A pan-steatotic liver disease treatment?[J]. Biomedicines, 2025, 13( 7): 1516. DOI: 10.3390/biomedicines13071516. [47] BRIAND F, DUBROCA C, WETTSTEIN G, et al. Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese Hamster models of MASH and MetALD[J]. Eur J Pharmacol, 2025, 1003: 177945. DOI: 10.1016/j.ejphar.2025.177945. [48] YUN B, PARK H, LEE J, et al. Statin use and liver-related prognosis among patients with MASLD[J]. JHEP Rep, 2025, 7( 4): 101313. DOI: 10.1016/j.jhepr.2024.101313. [49] LI Q, CHEN L. Understanding of the new concept of MetALD and the research progress of related drugs[J]. Chin Hepatol, 2025, 30( 1): 7- 10. DOI: 10.14000/j.cnki.issn.1008-1704.2025.01.003.李强, 陈良. 对MetALD新概念的认识以及相关药物研究进展[J]. 肝脏, 2025, 30( 1): 7- 10. DOI: 10.14000/j.cnki.issn.1008-1704.2025.01.003. [50] BAFFY G, MITTEN EK, PORTINCASA P. Is MetALD an all-inclusive term for liver disease caused by alcohol and metabolic dysfunction?[J]. J Hepatol, 2025, 83( 3): e166- e168. DOI: 10.1016/j.jhep.2025.05.012. [51] ACIERNO C, BARLETTA F, CATURANO A, et al. Alcohol consumption and liver metabolism in the era of MASLD: Integrating nutritional and pathophysiological insights[J]. Nutrients, 2025, 17( 13): 2229. DOI: 10.3390/nu17132229. [52] CHEN ST, YANG D, LI QJ, et al. Ameliorative effect of puerarin on non-alcoholic fatty liver disease induced by high-fat diet in mice and its mechanism[J]. J Jilin Univ(Med Edit), 2026, 52( 1): 44- 55. DOI: 10.13481/j.1671-587X.20260106.陈思童, 杨丹, 李庆杰, 等. 葛根素对高脂饮食诱导小鼠非酒精性脂肪性肝病的改善作用及其机制[J]. 吉林大学学报(医学版), 2026, 52( 1): 44- 55. DOI: 10.13481/j.1671-587X.20260106. [53] PAN YQ, MAO AJ, YU CC, et al. Active components of traditional Chinese medicine and their compound prescriptions in prevention and treatment of nonalcoholic fatty liver disease: Current status and prospects[J]. J Clin Hepatol, 2024, 40( 10): 1933- 1941. DOI: 10.12449/JCH241002.潘雨晴, 毛傲洁, 于楚楚, 等. 中药有效成分及其复方防治非酒精性脂肪性肝病的现状与展望[J]. 临床肝胆病杂志, 2024, 40( 10): 1933- 1941. DOI: 10.12449/JCH241002. [54] YAN XL, YANG L, LI Y. Application of Xiaozhi Shugan decoction in patients with non-alcoholic fatty liver disease[J]. J Changchun Univ Chin Med, 2026, 42( 2): 211- 215. DOI: 10.13463/j.cnki.cczyy.2026.02.018.严贤亮, 杨磊, 李莹. 消脂舒肝汤在非酒精性脂肪肝患者中的应用[J]. 长春中医药大学学报, 2026, 42( 2): 211- 215. DOI: 10.13463/j.cnki.cczyy.2026.02.018. [55] WANG WJ, GAO YH. The increasing burden of alcoholic liver disease in China[J]. J Clin Hepatol, 2019, 35( 9): 2044.王文君, 高沿航. 中国日益增加的酒精性肝病负担[J]. 临床肝胆病杂志, 2019, 35( 9): 2044. -
下载:
本文二维码
图(1)
计量
- 文章访问数: 13
- HTML全文浏览量: 3
- PDF下载量: 2
- 被引次数: 0
